Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies

Analysis of the recurrent genetic aberrations present in human tumors provides insight into how normal cells escape appropriate proliferation and survival cues. Commonly mutated genes encode proteins that monitor DNA damage (e.g., p53), proteins that regulate the cell cycle (such as Rb), and proteins that regulate signal transduction pathways (such as APC, PTEN and Ras). Analysis of the relevant targets and downstream events of these genes in normal and tumor cells will clearly highlight important pathways for tumorigenesis. However, more infrequent mutations are also informative in defining events critical for the process of tumorigenesis, and often delineate important pathways lying downstream of commonly mutated oncogenes and tumor suppressors. Together, these studies have led to the conclusion that deregulated protein synthesis plays an important role in human cancer. This review will discuss the evidence implicating mRNA translation as an important downstream consequence of signal transduction pathways initiated by mutated oncogenes and tumor suppressors, as well as additional genetic findings implicating the importance of global and specific translational control in human cancer. It will also discuss therapeutic strategies that take advantage of differences in translational regulation between normal and tumor cells.

[1]  J. Inazawa,et al.  PTK2 and EIF3S3 genes may be amplification targets at 8q23‐q24 and are associated with large hepatocellular carcinomas , 2003, Hepatology.

[2]  G. Thomas,et al.  14 Ribosomal Protein S6 Phosphorylation and Signal Transduction , 1996 .

[3]  M. Karin,et al.  Double-stranded RNA-dependent Protein Kinase Phosphorylation of the α-Subunit of Eukaryotic Translation Initiation Factor 2 Mediates Apoptosis* , 2006, Journal of Biological Chemistry.

[4]  D. Horn,et al.  Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. , 2005, American journal of human genetics.

[5]  K. Borden,et al.  eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR , 2005, The Journal of cell biology.

[6]  F. Couch,et al.  PS6K amplification characterizes a small subset of anaplastic meningiomas. , 2001, American journal of clinical pathology.

[7]  V. Velculescu,et al.  Implications of micro-RNA profiling for cancer diagnosis , 2006, Oncogene.

[8]  Kei Sakamoto,et al.  LKB1-dependent signaling pathways. , 2006, Annual review of biochemistry.

[9]  R. Pincheira,et al.  Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth , 2004, Oncogene.

[10]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Yuval Dor,et al.  Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.

[12]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[13]  Nancy Hopkins,et al.  Many Ribosomal Protein Genes Are Cancer Genes in Zebrafish , 2004, PLoS biology.

[14]  M. Rosbash,et al.  A Drosophila Minute gene encodes a ribosomal protein , 1985, Nature.

[15]  D. Alessi,et al.  TSC1–TSC2: a complex tale of PKB-mediated S6K regulation , 2002, Nature Cell Biology.

[16]  Francesco Piazza,et al.  Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification , 2003, Science.

[17]  B. Law,et al.  Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. , 2006, Cancer research.

[18]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[19]  T. Fukuchi-Shimogori,et al.  Malignant transformation by overproduction of translation initiation factor eIF4G. , 1997, Cancer research.

[20]  Z. Salehi,et al.  Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. , 2006, Clinical biochemistry.

[21]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Tominaga,et al.  Translational Deregulation in PDK-1−/− Embryonic Stem Cells , 2005, Molecular and Cellular Biology.

[23]  B. Calabretta,et al.  Translational regulation by the p210 BCR/ABL oncoprotein , 2004, Oncogene.

[24]  N. Sonenberg,et al.  mTOR, translation initiation and cancer , 2006, Oncogene.

[25]  R. Pearson,et al.  Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k , 1997, The EMBO journal.

[26]  K. Klempnauer,et al.  The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA , 2003, Oncogene.

[27]  N. Colburn,et al.  Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. , 2004, Molecular cancer therapeutics.

[28]  A. Gingras,et al.  Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.

[29]  S. Ellis,et al.  Ribosomes and marrow failure: coincidental association or molecular paradigm? , 2006, Blood.

[30]  M. Takagi,et al.  Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin , 2005, Cell.

[31]  C. James,et al.  Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. , 2005, Neoplasia.

[32]  Naomi R Wray,et al.  Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours , 2005, BMC Cancer.

[33]  K. Norman,et al.  Systemic reovirus therapy of metastatic cancer in immune-competent mice. , 2003, Cancer research.

[34]  A. De Benedetti,et al.  eIF4E expression in tumors: its possible role in progression of malignancies. , 1999, The international journal of biochemistry & cell biology.

[35]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[36]  Benjamin D. L. Li,et al.  Progression of eIF4E gene amplification and overexpression in benign and malignant tumors of the head and neck , 2000, Cancer.

[37]  A. Benedetti,et al.  Selective killing of cancer cells based on translational control of a suicide gene , 2002, Cancer Gene Therapy.

[38]  G. Barber,et al.  Defective translational control facilitates vesicular stomatitis virus oncolysis. , 2004, Cancer cell.

[39]  P. Vogt,et al.  Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation , 2005, Molecular and Cellular Biology.

[40]  A. Marchetti,et al.  Int6 Expression Can Predict Survival in Early-Stage Non–Small Cell Lung Cancer Patients , 2005, Clinical Cancer Research.

[41]  King-Jen Chang,et al.  Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome , 2004, Journal of surgical oncology.

[42]  K. Norman,et al.  Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer , 2004, Gene Therapy.

[43]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Gregory,et al.  Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis. , 2005, Angewandte Chemie.

[45]  A. Levine,et al.  The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes , 1994, Molecular and cellular biology.

[46]  D. Menick,et al.  Regulation of protein synthesis by eIF4E phosphorylation in adult cardiocytes: the consequence of secondary structure in the 5'-untranslated region of mRNA. , 2004, The Biochemical journal.

[47]  L. Comai,et al.  Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53 , 2000, Molecular and Cellular Biology.

[48]  G. Mills,et al.  Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[49]  Brett L Carlson,et al.  Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.

[50]  S. Morley The regulation of eIF4F during cell growth and cell death. , 2001, Progress in molecular and subcellular biology.

[51]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[52]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[53]  J. Steitz,et al.  The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[55]  M. R. Duncan,et al.  Differential sensitivity of normal and transformed human cells to reovirus infection , 1978, Journal of virology.

[56]  S. Kulkarni,et al.  Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[58]  B. Hilliard,et al.  Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 41 , 2006, The Journal of Immunology.

[59]  D. Pospíšilová,et al.  Translational efficiency in patients with Diamond-Blackfan anemia. , 2006, Haematologica.

[60]  N. Sigal,et al.  Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. , 1990, Journal of immunology.

[61]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[62]  Mu-xiang Zhou,et al.  Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer , 2006, BMC Cancer.

[63]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[64]  F. Couch,et al.  Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. , 1999, Cancer research.

[65]  N. Sonenberg,et al.  Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation , 2007, PloS one.

[66]  J. Fando,et al.  4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. , 2000, The international journal of biochemistry & cell biology.

[67]  K. Norman,et al.  Reovirus oncolysis of human breast cancer. , 2002, Human gene therapy.

[68]  G. Barber,et al.  Vesicular Stomatitis Virus (VSV) Therapy of Tumors , 2000, IUBMB life.

[69]  邓伟平,et al.  Dyskeratosis congenita , 2007 .

[70]  Konstantin G. Chernov,et al.  The mRNA-binding Protein YB-1 (p50) Prevents Association of the Eukaryotic Initiation Factor eIF4G with mRNA and Inhibits Protein Synthesis at the Initiation Stage* , 2003, The Journal of Biological Chemistry.

[71]  Stefano Volinia,et al.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[72]  I. Mellinghoff,et al.  AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* , 2004, Journal of Biological Chemistry.

[73]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[74]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  O. Meyuhas,et al.  Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. , 2006, Trends in biochemical sciences.

[76]  F. Laski,et al.  string of pearls encodes Drosophila ribosomal protein S2, has Minute-like characteristics, and is required during oogenesis. , 1994, Genetics.

[77]  Roger L. Williams,et al.  Phosphoinositide 3-kinases as drug targets in cancer. , 2005, Current opinion in pharmacology.

[78]  T. Takagi,et al.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. , 2001, Cancer research.

[79]  G. Thomas,et al.  Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Isaac Bentwich Prediction and validation of microRNAs and their targets , 2005, FEBS letters.

[81]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[82]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[83]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.

[84]  B. Bay,et al.  Significance of the Y-box proteins in human cancers , 2005, Journal of molecular and genetic medicine : an international journal of biomedical research.

[85]  K. Norman,et al.  Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Coffey,et al.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus , 1998, The EMBO journal.

[87]  Raffaele Fronza,et al.  Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. , 2006, Carcinogenesis.

[88]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[89]  M. Peterson,et al.  Translation Factor eIF4E Rescues Cells from Myc-dependent Apoptosis by Inhibiting Cytochromec Release* , 2003, The Journal of Biological Chemistry.

[90]  K. Norman,et al.  Oncolytic reovirus against ovarian and colon cancer. , 2002, Cancer research.

[91]  P. Vogt,et al.  Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[92]  K. Collins,et al.  Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. , 2006, Genes & development.

[93]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[94]  J. Avruch,et al.  Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[95]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[96]  Akihiko Nomura,et al.  Reduced Gene Expression of Clustered Ribosomal Proteins in Diamond-Blackfan Anemia Patients Without RPS19 Gene Mutations , 2006, Journal of pediatric hematology/oncology.

[97]  Wei Xu,et al.  Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita , 2006, Science.

[98]  B. Hemmings,et al.  Physiological functions of protein kinase B/Akt. , 2004, Biochemical Society transactions.

[99]  W. Friedrichs,et al.  Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  E. B. Butler,et al.  Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[101]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[102]  Michele Pagano,et al.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. , 2006, Science.

[103]  R. Kaufman 13 The Double-stranded RNA-activated Protein Kinase PKR , 2000 .

[104]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[105]  H. Iro,et al.  Translation initiation factor eIF‐4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma , 2001, Cancer.

[106]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[107]  S. Zimmer,et al.  Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs , 2004, Clinical & Experimental Metastasis.

[108]  D. Stokoe The phosphoinositide 3-kinase pathway and cancer , 2005, Expert Reviews in Molecular Medicine.

[109]  M. Gleave,et al.  Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter , 2006, Cancer Gene Therapy.

[110]  M. Schmitt,et al.  RNase MRP Cleaves the CLB2 mRNA To Promote Cell Cycle Progression: Novel Method of mRNA Degradation , 2004, Molecular and Cellular Biology.

[111]  S. Karlsson,et al.  Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. , 2007, Blood.

[112]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[113]  T. Visakorpi,et al.  Mapping the amplification of EIF3S3 in breast and prostate cancer , 2000, Genes, chromosomes & cancer.

[114]  D. Hallahan,et al.  Enhanced radiation damage of tumor vasculature by mTOR inhibitors , 2005, Oncogene.

[115]  E. Schmidt The role of c-myc in regulation of translation initiation , 2004, Oncogene.

[116]  Peter Gustavsson,et al.  The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia , 1999, Nature Genetics.

[117]  J. Eberle,et al.  Translation initiation factor eIF‐4A1 mRNA is consistently overexpressed in human melanoma cells in vitro , 1997, International journal of cancer.

[118]  Jian-Ting Zhang,et al.  EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. , 2003, Molecular biology of the cell.

[119]  池田 万里郎,et al.  318 子宮内膜における Double-Stranded RNA-Activated Protein Kinase (PKR)の遺伝子発現とインターフェロンによるその誘導 , 1999 .

[120]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[121]  M. Dai,et al.  Regulation of the MDM2-p53 Pathway by Ribosomal Protein L11 Involves a Post-ubiquitination Mechanism* , 2006, Journal of Biological Chemistry.

[122]  J. Gray,et al.  Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer , 2002, Nature Genetics.

[123]  T. P. B. Handley,et al.  Dyskeratosis congenita. , 2006, Oral oncology.

[124]  N. Sonenberg,et al.  Translational control of gene expression , 2000 .

[125]  C. Proud,et al.  Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase , 2001, The EMBO journal.

[126]  S. Hanash,et al.  Global and Specific Translational Control by Rapamycin in T Cells Uncovered by Microarrays and Proteomics* , 2002, The Journal of Biological Chemistry.

[127]  H. Atkins,et al.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.

[128]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[129]  A. Gingras,et al.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases , 2004, The EMBO journal.

[130]  M. Berger,et al.  mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.

[131]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[132]  David Tollervey,et al.  Ribosome synthesis meets the cell cycle. , 2004, Current opinion in microbiology.

[133]  Jacqueline Noaillac-Depeyre,et al.  Impaired ribosome biogenesis in Diamond-Blackfan anemia. , 2007, Blood.

[134]  María A Blasco,et al.  Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.

[135]  A. De Benedetti,et al.  Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[136]  N. Hay,et al.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.

[137]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[138]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[139]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[140]  A. Chapelle,et al.  Mutations in the RNA Component of RNase MRP Cause a Pleiotropic Human Disease, Cartilage-Hair Hypoplasia , 2001, Cell.

[141]  D. Kwiatkowski,et al.  Tuberous Sclerosis: from Tubers to mTOR , 2003, Annals of human genetics.

[142]  N. Sonenberg,et al.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. , 2004, Cancer cell.

[143]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[144]  N. Sonenberg,et al.  Akt-Mediated YB-1 Phosphorylation Activates Translation of Silent mRNA Species , 2006, Molecular and Cellular Biology.

[145]  T. Vulliamy,et al.  Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. , 2006, Blood.

[146]  G. Weber,et al.  The molecular correlation concept of neoplasia. , 1966, Advances in enzyme regulation.

[147]  C. Downes,et al.  PTEN: The down side of PI 3-kinase signalling. , 2002, Cellular signalling.

[148]  E. Holland,et al.  Postgenomic global analysis of translational control induced by oncogenic signaling , 2004, Oncogene.

[149]  Claes Wahlestedt,et al.  Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure , 2006, Nucleic acids research.

[150]  N. Sonenberg,et al.  Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Isaac S Kohane,et al.  Defective Ribosomal Protein Gene Expression Alters Transcription, Translation, Apoptosis, and Oncogenic Pathways in Diamond‐Blackfan Anemia , 2006, Stem cells.

[152]  N. Sonenberg,et al.  The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation , 2003, Molecular and Cellular Biology.

[153]  J. Avruch,et al.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR , 2000, Current Biology.

[154]  I. Grummt,et al.  Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases , 2006, Oncogene.

[155]  E. Schmidt,et al.  Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth* , 2004, Journal of Biological Chemistry.

[156]  D. Guertin,et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.

[157]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[158]  Eva Dizin,et al.  BRCA1 Interacts with Poly(A)-binding Protein , 2006, Journal of Biological Chemistry.

[159]  J. Mathis,et al.  Cancer‐specific targeting of an adenovirus‐delivered herpes simplex virus thymidine kinase suicide gene using translational control , 2006, The journal of gene medicine.

[160]  S. Karlsson,et al.  Erythropoiesis in the Rps19 disrupted mouse: Analysis of erythropoietin response and biochemical markers for Diamond-Blackfan anemia. , 2006, Blood cells, molecules & diseases.

[161]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[162]  Jian-Ting Zhang,et al.  Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. , 2006, Critical reviews in oncology/hematology.

[163]  J. Hershey,et al.  Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells , 2006, Oncogene.

[164]  A. Ryo,et al.  Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. , 2000, Anticancer research.

[165]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[166]  N. Sonenberg,et al.  Abrogation of translation initiation factor eIF‐2 phosphorylation causes malignant transformation of NIH 3T3 cells. , 1995, The EMBO journal.

[167]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[168]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[169]  C. Tokunaga,et al.  Kinase activities associated with mTOR. , 2004, Current topics in microbiology and immunology.

[170]  A. Wlodawer,et al.  Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. , 2005, RNA.

[171]  T. Cloughesy,et al.  Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. , 2006, Cancer research.

[172]  A. De Benedetti,et al.  Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis , 1996, International journal of cancer.

[173]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[174]  C. Meschonat,et al.  High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer , 2006, Annals of surgery.

[175]  N. Sonenberg,et al.  Akt Activates the Mammalian Target of Rapamycin by Regulating Cellular ATP Level and AMPK Activity* , 2005, Journal of Biological Chemistry.

[176]  F. Jiang,et al.  Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach , 2006, Oncogene.

[177]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.